Patrick Soon-Shiong
Fondateur chez IMMUNITYBIO, INC.
Fortune : 1 392 M $ au 30/04/2024
Relations actives
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Bruce Wendel | M | 70 |
Abraxis BioScience, Inc. /Old/
 Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL
American Pharmaceutical Partners, Inc.
 American Pharmaceutical Partners, Inc. Pharmaceuticals: MajorHealth Technology American Pharmaceutical Partners, Inc. is engaged in to developing, manufacturing and marketing injectable pharmaceutical products. The company produces generic injectable pharmaceutical products in more than 300 dosages and formulations. The company focuses mainly in the oncology, anti-infective and critical care markets. The company is located in Schaumburg, IL.
Abraxis Health, Inc.
 Abraxis Health, Inc. BiotechnologyHealth Technology Abraxis Health is establishing as a fully-integrated, next-generation, evidence-based, and personalized healthcare company. It plans to develop a proprietary model for the delivery of healthcare. Abraxis Health is designing and acquiring the necessary infrastructure and plans to acquire and internally develop the hardware and software modules to organize and integrate the data streams that form the foundation of an interactive database. The firm will develop, test, and validate diagnostics and drugs to target pre-selected patients based on molecular profiles that predict drug response to particular therapeutics.
Abraxis BioScience, Inc.
 Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 8 ans |
| Michael Blaszyk | M | 71 |
Fresenius Kabi Pharmaceuticals Holding LLC
 Fresenius Kabi Pharmaceuticals Holding LLC Pharmaceuticals: MajorHealth Technology Fresenius Kabi Pharmaceuticals Holding LLC is a pharmaceutical company, which engages in the development, manufacturing, and marketing of injectable pharmaceutical products. It primarily focuses on the injectable oncology, anti-infective, anesthetic/analgesic, and critical care markets. The firm manufactures products in each of the three basic forms, which include liquid, powder, and lyophilized or freeze-dried. Its products are generally used in hospitals, long-term care facilities, alternate care sites and clinics. The company was founded on July 2, 2008 and is headquartered in Wilmington, DE.
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL | 12 ans |
| Kirk Calhoun | M | 80 |
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL
American Pharmaceutical Partners, Inc.
American Pharmaceutical Partners, Inc. Pharmaceuticals: MajorHealth Technology American Pharmaceutical Partners, Inc. is engaged in to developing, manufacturing and marketing injectable pharmaceutical products. The company produces generic injectable pharmaceutical products in more than 300 dosages and formulations. The company focuses mainly in the oncology, anti-infective and critical care markets. The company is located in Schaumburg, IL.
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 17 ans |
| Frank R. Jones | M | - |
Etubics Corp.
 Etubics Corp. BiotechnologyHealth Technology Etubics Corp. develops commercial prophylactic vaccines and immunotherapy products. It offers proprietary immunization platform technology called the etubics platform that develops therapeutic vaccines for colon and breast cancers and preventative vaccines for H1N1 Influenza and HIV. The company was founded by Frank R. Jones in 2003 and is headquartered in Seattle, WA. | 21 ans |
| Barry Simon | M | 59 | 17 ans | |
| David Sachs | M | 46 |
Chan Soon-Shiong Institute For Medicine
 Chan Soon-Shiong Institute For Medicine Medical/Nursing ServicesHealth Services The Chan Soon-Shiong Institute for Medicine, Immuno-Oncology Network, is a cancer center that provides advanced diagnosis, treatment, and clinical trials for cancer patients. The private company is based in El Segundo. The center is staffed by a team of experienced medical professionals who are dedicated to providing personalized care. The CEO of the American company is Patrick Soon-Shiong.
Keyssa, Inc.
 Keyssa, Inc. Electronic ComponentsElectronic Technology Keyssa, Inc. develops connectors. It offers wireless transfer of data and video between devices with speed. The company was founded by Gary McCormack and Ira Deyhimy in 2009 and is headquartered in Campbell, CA. | 6 ans |
| Carol R. Jones | F | - |
Etubics Corp.
Etubics Corp. BiotechnologyHealth Technology Etubics Corp. develops commercial prophylactic vaccines and immunotherapy products. It offers proprietary immunization platform technology called the etubics platform that develops therapeutic vaccines for colon and breast cancers and preventative vaccines for H1N1 Influenza and HIV. The company was founded by Frank R. Jones in 2003 and is headquartered in Seattle, WA. | - |
| Peter Witonsky | M | - |
iSirona LLC
 iSirona LLC Packaged SoftwareTechnology Services iSirona LLC is engaged in the provision of software solutions for medical device integration. It helps hospitals leverage patient data through a device and wireless connectivity. The company was founded by David Dyell in 2008 and is headquartered in Panama City, FL. | - |
| Christobel Selecky | F | 69 |
NantCell, Inc.
 NantCell, Inc. Pharmaceuticals: MajorHealth Technology NantCell, Inc. focuses on treating immunology diseases. It offers cell-based treatments at the molecular level. The firm develops molecularly designed drugs for genomics and proteomics and identify patients and their tumor signature at the granular cellular, DNA and protein levels. The company was founded by Patrick Soon-Shiong in 2014 and is headquartered in Culver City, CA. | 4 ans |
| Richard Adcock | M | 55 | 4 ans | |
| John Brennan | M | 67 |
NantCell, Inc.
NantCell, Inc. Pharmaceuticals: MajorHealth Technology NantCell, Inc. focuses on treating immunology diseases. It offers cell-based treatments at the molecular level. The firm develops molecularly designed drugs for genomics and proteomics and identify patients and their tumor signature at the granular cellular, DNA and protein levels. The company was founded by Patrick Soon-Shiong in 2014 and is headquartered in Culver City, CA. | 3 ans |
| Mark Burnett | M | 63 |
Nantbio, Inc.
 Nantbio, Inc. Pharmaceuticals: MajorHealth Technology Nantbio, Inc. is a biopharmaceutical company that develops molecular drugs. The company is based in El Segundo, CA. The CEO of the company is Patrick Soon-Shiong. | 3 ans |
| John Robert Ducker | M | 64 |
Fresenius Kabi Pharmaceuticals Holding LLC
Fresenius Kabi Pharmaceuticals Holding LLC Pharmaceuticals: MajorHealth Technology Fresenius Kabi Pharmaceuticals Holding LLC is a pharmaceutical company, which engages in the development, manufacturing, and marketing of injectable pharmaceutical products. It primarily focuses on the injectable oncology, anti-infective, anesthetic/analgesic, and critical care markets. The firm manufactures products in each of the three basic forms, which include liquid, powder, and lyophilized or freeze-dried. Its products are generally used in hospitals, long-term care facilities, alternate care sites and clinics. The company was founded on July 2, 2008 and is headquartered in Wilmington, DE. | 14 ans |
| Alan W. Portela | M | 62 |
AirStrip Technologies, Inc.
 AirStrip Technologies, Inc. Specialty TelecommunicationsCommunications AirStrip Technologies, Inc. engages in provision of mobile medical software applications. It offers AirStrip ONE, a digital healthcare platform which delivers business intelligence advantage essential for continuous performance improvement. Its platform is used for digital electrocardiogram snippets, alarm management, remote patient waveforms, ST-Elevation Myocardial Infarction (STEMI) notification, mobile 12-Lead ECG access, electronic ECG management, and maternal/fetal waveform cases. The company was founded by Stephen Moore and William Eugene Powell in 2004 and is headquartered in San Antonio, TX. | 13 ans |
| Wesley Clark | M | 78 |
NantCell, Inc.
NantCell, Inc. Pharmaceuticals: MajorHealth Technology NantCell, Inc. focuses on treating immunology diseases. It offers cell-based treatments at the molecular level. The firm develops molecularly designed drugs for genomics and proteomics and identify patients and their tumor signature at the granular cellular, DNA and protein levels. The company was founded by Patrick Soon-Shiong in 2014 and is headquartered in Culver City, CA. | 3 ans |
| Brandon Villery | M | - |
NantWorks LLC
 NantWorks LLC Information Technology ServicesTechnology Services NantWorks LLC develops technology based semiconductor and advanced networks for healthcare improvements. Its solution is for life threatening diseases such as cancer, infectious diseases and Alzheimer’s. The company was founded by Patrick Soon-Shiong in September 2011 and is headquartered in Culver City, CA. | 4 ans |
| Fred Middleton | M | 74 |
Altor BioScience Corp.
 Altor BioScience Corp. Pharmaceuticals: MajorHealth Technology Altor BioScience Corp. operates as a biopharmaceutical company which develops therapeutic products for the treatment of cancer. Its product candidates include ALT-801, a T-cell receptor-targeted immunotherapeutic for cancer and ALT-836, a monoclonal antibody-based tissue factor antagonist treatment of patients with acute respiratory distress syndrome and acute lung injury. The company was founded by Hing C. Wong in 2002 and is headquartered in Miramar, FL. | 19 ans |
| Charles Hunt | M | - | - | |
| Edward C. Geehr | M | 75 |
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA.
Abraxis Health, Inc.
Abraxis Health, Inc. BiotechnologyHealth Technology Abraxis Health is establishing as a fully-integrated, next-generation, evidence-based, and personalized healthcare company. It plans to develop a proprietary model for the delivery of healthcare. Abraxis Health is designing and acquiring the necessary infrastructure and plans to acquire and internally develop the hardware and software modules to organize and integrate the data streams that form the foundation of an interactive database. The firm will develop, test, and validate diagnostics and drugs to target pre-selected patients based on molecular profiles that predict drug response to particular therapeutics. | 2 ans |
| Ben Zamanzadeh | M | - |
University of California, Los Angeles
| - |
| Siavash M. Alamouti | M | - |
Tensorcom, Inc.
 Tensorcom, Inc. SemiconductorsElectronic Technology Tensorcom, Inc. fabless semiconductor company. It develops technologies for wireless personal and local area networks. The company was founded by Patrick Soon-Shiong and is headquartered in San Diego, CA. | - |
| Mickie Rosen | F | 56 |
Los Angeles Times Media Group
 Los Angeles Times Media Group Advertising/Marketing ServicesCommercial Services Part of Nant Capital LLC, Los Angeles Times Media Group is a company that provides advertising services. The company is based in Los Angeles, CA. Mickie Rosen has been the CEO of the company since 2017. | 7 ans |
| R. Naseem | M | 57 | 1 ans | |
| Jason R. Liljestrom | M | 41 | - | |
| Christopher H. Argentieri | M | - |
Los Angeles Times Communications LLC
 Los Angeles Times Communications LLC Publishing: NewspapersConsumer Services Los Angeles Times Communications LLC engages in the publication of newspapers. The firm offers entertainment news and reviews and Southern California's event listing. The company was founded on December 4, 1881 and is headquartered in Los Angeles, CA. | 10 ans |
| Elizabeth S. Gabitzsch | F | - |
Etubics Corp.
Etubics Corp. BiotechnologyHealth Technology Etubics Corp. develops commercial prophylactic vaccines and immunotherapy products. It offers proprietary immunization platform technology called the etubics platform that develops therapeutic vaccines for colon and breast cancers and preventative vaccines for H1N1 Influenza and HIV. The company was founded by Frank R. Jones in 2003 and is headquartered in Seattle, WA. | - |
| Thomas Chuck Ensign | M | - |
Nantenergy, Inc.
 Nantenergy, Inc. Electrical ProductsProducer Manufacturing Nantenergy, Inc. provides energy storage products. It develops a breakthrough rechargeable metal-air battery, which contains energy metals and utilizes free atmospheric oxygen to store large amounts of energy. The firm’s products include back-up power, diesel generator replacement, electric grid optimization, and renewable energy integration. The company was founded by Cody Friesen in 2011 and is headquartered in Scottsdale, AZ. | - |
| Charles C. Kim | M | - |
NantWorks LLC
NantWorks LLC Information Technology ServicesTechnology Services NantWorks LLC develops technology based semiconductor and advanced networks for healthcare improvements. Its solution is for life threatening diseases such as cancer, infectious diseases and Alzheimer’s. The company was founded by Patrick Soon-Shiong in September 2011 and is headquartered in Culver City, CA.
Etubics Corp.
Etubics Corp. BiotechnologyHealth Technology Etubics Corp. develops commercial prophylactic vaccines and immunotherapy products. It offers proprietary immunization platform technology called the etubics platform that develops therapeutic vaccines for colon and breast cancers and preventative vaccines for H1N1 Influenza and HIV. The company was founded by Frank R. Jones in 2003 and is headquartered in Seattle, WA. | 13 ans |
| Sandeep K. Reddy | M | - | 8 ans | |
| Johanna Maska | F | - |
Los Angeles Times Media Group
Los Angeles Times Media Group Advertising/Marketing ServicesCommercial Services Part of Nant Capital LLC, Los Angeles Times Media Group is a company that provides advertising services. The company is based in Los Angeles, CA. Mickie Rosen has been the CEO of the company since 2017. | - |
| Sarah Singleton | F | - | 4 ans | |
| John Lee | M | 56 |
NantCell, Inc.
NantCell, Inc. Pharmaceuticals: MajorHealth Technology NantCell, Inc. focuses on treating immunology diseases. It offers cell-based treatments at the molecular level. The firm develops molecularly designed drugs for genomics and proteomics and identify patients and their tumor signature at the granular cellular, DNA and protein levels. The company was founded by Patrick Soon-Shiong in 2014 and is headquartered in Culver City, CA. | 5 ans |
| Linda Maxwell | M | 50 | 3 ans | |
| Justin Dooley | M | - |
The National Institute of Transplantation
 The National Institute of Transplantation Miscellaneous Commercial ServicesCommercial Services Part of Eurofins Scientific SE, The National Institute of Transplantation is a company that undertakes transplantation research. The company is based in Los Angeles, CA. Justin Dooley has been the CEO of the company since 2003. The National Institute of Transplantation was acquired by Eurofins Viracor, Inc., part of Eurofins Scientific SE from July 01, 2014 on December 10, 2013. | 21 ans |
| A. Brent Eastman | M | - |
American College of Surgeons Oncology Group
 American College of Surgeons Oncology Group Medical/Nursing ServicesHealth Services The American College of Surgeons Oncology Group (ACOSOG) was established to evaluate the surgical management of patients with malignant solid tumors. ACOSOG is one of 10 cooperative groups funded by the National Cancer Institute (NCI) to develop and coordinate multi-institutional clinical trials. ACOSOG is the only cooperative group with studies focusing primarily on surgical objectives. ACOSOG currently has treatment protocols available in three major disease areas: . Breast Cancer . Gastrointestinal Cancer . Thoracic Cancer ACOSOG is composed of the Operations and Membership Center located at the Duke Clinical Research Institute on the Duke University Medical Center campus and the Statistics and Data Center located at the Mayo Clinic Cancer Center. ACOSOG's membership is comprised of investigators and research associates representing oncology treatment modalities and research-related concerns, including surgery, medical oncology, radiation oncology, diagnostic imaging, pathology, ethics, CRA/nursing and patient advocacy. | - |
| Robert L. Comis | M | - |
eviti, Inc.
 eviti, Inc. Medical/Nursing ServicesHealth Services Part of NantHealth, Inc., eviti, Inc. streamlines treatment plan validation for cancer treatment. The company is based in Philadelphia, PA. The company's mission is to enter prescribed treatment plans online, minimize calls to the health plan, and reduce denials and appeals. | - |
| Scott W. Meacham | M | 64 |
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL
Fresenius Kabi Pharmaceuticals Holding LLC
Fresenius Kabi Pharmaceuticals Holding LLC Pharmaceuticals: MajorHealth Technology Fresenius Kabi Pharmaceuticals Holding LLC is a pharmaceutical company, which engages in the development, manufacturing, and marketing of injectable pharmaceutical products. It primarily focuses on the injectable oncology, anti-infective, anesthetic/analgesic, and critical care markets. The firm manufactures products in each of the three basic forms, which include liquid, powder, and lyophilized or freeze-dried. Its products are generally used in hospitals, long-term care facilities, alternate care sites and clinics. The company was founded on July 2, 2008 and is headquartered in Wilmington, DE. | 18 ans |
| Cheryl Cohen | F | 58 | 5 ans | |
| Kishore Kumar Lulla | M | 62 |
University of California, Los Angeles
| - |
| Robert J. Abernethy | M | 84 |
University of California, Los Angeles
| - |
| Gary S. Lazar | M | - |
University of California, Los Angeles
| - |
| Amy Pascal | F | - |
University of California, Los Angeles
| - |
| Eleazar Eskin | M | - |
University of California, Los Angeles
| - |
| David B. Agus | M | - |
University of California, Los Angeles
| - |
| Alexander Bystritsky | M | - |
University of California, Los Angeles
| - |
| Ronald Sarian | M | - |
University of California, Los Angeles
| - |
| Stuart J. Levy | M | - |
University of California, Los Angeles
| - |
| Frank Litvak | M | - |
University of California, Los Angeles
| 24 ans |
| Gregory Lynn | M | 59 |
University of California, Los Angeles
| 24 ans |
| Richard Fitch | M | - |
University of California, Los Angeles
| - |
| Susanna E. Bennett | F | - |
University of California, Los Angeles
| - |
| Frank Litvack | M | 68 |
University of California, Los Angeles
| - |
| Henri R. Ford | M | - |
American College of Surgeons Oncology Group
American College of Surgeons Oncology Group Medical/Nursing ServicesHealth Services The American College of Surgeons Oncology Group (ACOSOG) was established to evaluate the surgical management of patients with malignant solid tumors. ACOSOG is one of 10 cooperative groups funded by the National Cancer Institute (NCI) to develop and coordinate multi-institutional clinical trials. ACOSOG is the only cooperative group with studies focusing primarily on surgical objectives. ACOSOG currently has treatment protocols available in three major disease areas: . Breast Cancer . Gastrointestinal Cancer . Thoracic Cancer ACOSOG is composed of the Operations and Membership Center located at the Duke Clinical Research Institute on the Duke University Medical Center campus and the Statistics and Data Center located at the Mayo Clinic Cancer Center. ACOSOG's membership is comprised of investigators and research associates representing oncology treatment modalities and research-related concerns, including surgery, medical oncology, radiation oncology, diagnostic imaging, pathology, ethics, CRA/nursing and patient advocacy. | - |
| Robert G. Koblin | M | 92 |
University of California, Los Angeles
| 42 ans |
| Ronald H. Wender | M | 77 |
University of California, Los Angeles
| - |
| James I. Ausman | M | 86 |
University of California, Los Angeles
| 19 ans |
| James A. McKinnell | M | - |
University of California, Los Angeles
| - |
| C. Kumar N. Patel | M | 85 |
University of California, Los Angeles
| 24 ans |
| Mike Gyulai | M | - |
University of California, Los Angeles
| - |
| Tessa Kaganoff | F | - |
University of California, Los Angeles
| - |
| Mark H. Hyman | M | - |
University of California, Los Angeles
| - |
| Paul Stannard | M | - |
University of California, Los Angeles
| - |
| Ronald J. Pion | M | - |
University of California, Los Angeles
| - |
| Teodoro Forcht-Dagi | M | 75 |
American College of Surgeons Oncology Group
American College of Surgeons Oncology Group Medical/Nursing ServicesHealth Services The American College of Surgeons Oncology Group (ACOSOG) was established to evaluate the surgical management of patients with malignant solid tumors. ACOSOG is one of 10 cooperative groups funded by the National Cancer Institute (NCI) to develop and coordinate multi-institutional clinical trials. ACOSOG is the only cooperative group with studies focusing primarily on surgical objectives. ACOSOG currently has treatment protocols available in three major disease areas: . Breast Cancer . Gastrointestinal Cancer . Thoracic Cancer ACOSOG is composed of the Operations and Membership Center located at the Duke Clinical Research Institute on the Duke University Medical Center campus and the Statistics and Data Center located at the Mayo Clinic Cancer Center. ACOSOG's membership is comprised of investigators and research associates representing oncology treatment modalities and research-related concerns, including surgery, medical oncology, radiation oncology, diagnostic imaging, pathology, ethics, CRA/nursing and patient advocacy. | - |
| Vwani Roychowdhury | M | - |
University of California, Los Angeles
| - |
| Michel F. Lévesque | M | - |
University of California, Los Angeles
| - |
| Brad Spellberg | M | - |
University of California, Los Angeles
| - |
| Antonia Hernández | F | 75 |
University of California, Los Angeles
| - |
| Hans Klingemann | M | 74 | - | |
| Eli Gang | M | - |
University of California, Los Angeles
| - |
| Matthew Pulver | M | - |
University of California, Los Angeles
| - |
| Paul Skudder | M | - |
American College of Surgeons Oncology Group
American College of Surgeons Oncology Group Medical/Nursing ServicesHealth Services The American College of Surgeons Oncology Group (ACOSOG) was established to evaluate the surgical management of patients with malignant solid tumors. ACOSOG is one of 10 cooperative groups funded by the National Cancer Institute (NCI) to develop and coordinate multi-institutional clinical trials. ACOSOG is the only cooperative group with studies focusing primarily on surgical objectives. ACOSOG currently has treatment protocols available in three major disease areas: . Breast Cancer . Gastrointestinal Cancer . Thoracic Cancer ACOSOG is composed of the Operations and Membership Center located at the Duke Clinical Research Institute on the Duke University Medical Center campus and the Statistics and Data Center located at the Mayo Clinic Cancer Center. ACOSOG's membership is comprised of investigators and research associates representing oncology treatment modalities and research-related concerns, including surgery, medical oncology, radiation oncology, diagnostic imaging, pathology, ethics, CRA/nursing and patient advocacy. | - |
| Pejman Salimpour | M | - |
University of California, Los Angeles
| - |
| John Villasenor | M | - |
University of California, Los Angeles
| 32 ans |
| Joshua Freedman | M | - |
University of California, Los Angeles
| - |
| Craig Edward Ehrlich | M | 69 |
University of California, Los Angeles
| - |
| Francie Berns | F | - |
Los Angeles Times Media Group
Los Angeles Times Media Group Advertising/Marketing ServicesCommercial Services Part of Nant Capital LLC, Los Angeles Times Media Group is a company that provides advertising services. The company is based in Los Angeles, CA. Mickie Rosen has been the CEO of the company since 2017. | 18 ans |
| Carolina Reyes | M | - |
University of California, Los Angeles
| - |
| James S. Economou | M | - |
University of California, Los Angeles
| 38 ans |
| Peter Cowen | M | - |
University of California, Los Angeles
| - |
| Andrew Yeiser | M | 98 |
University of California, Los Angeles
| - |
| Martin Pops | M | - |
University of California, Los Angeles
| - |
| Alfred Warsavsky | M | - |
University of California, Los Angeles
| - |
| Antoni Ribas | M | 58 |
University of California, Los Angeles
| - |
| Ron Burkle | M | 70 |
University of California, Los Angeles
| - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Michael S. Sitrick | M | 76 |
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 9 ans |
| Jeff Yordon | M | 75 |
American Pharmaceutical Partners, Inc.
American Pharmaceutical Partners, Inc. Pharmaceuticals: MajorHealth Technology American Pharmaceutical Partners, Inc. is engaged in to developing, manufacturing and marketing injectable pharmaceutical products. The company produces generic injectable pharmaceutical products in more than 300 dosages and formulations. The company focuses mainly in the oncology, anti-infective and critical care markets. The company is located in Schaumburg, IL. | 10 ans |
| Carlo Montagner | M | 56 |
American Bioscience, Inc.
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 5 ans |
| Lonnie Moulder | M | 66 |
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 1 ans |
| David Chen | M | 76 |
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL
American Pharmaceutical Partners, Inc.
American Pharmaceutical Partners, Inc. Pharmaceuticals: MajorHealth Technology American Pharmaceutical Partners, Inc. is engaged in to developing, manufacturing and marketing injectable pharmaceutical products. The company produces generic injectable pharmaceutical products in more than 300 dosages and formulations. The company focuses mainly in the oncology, anti-infective and critical care markets. The company is located in Schaumburg, IL.
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 13 ans |
| Stephen D. Nimer | M | 70 |
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL
American Pharmaceutical Partners, Inc.
American Pharmaceutical Partners, Inc. Pharmaceuticals: MajorHealth Technology American Pharmaceutical Partners, Inc. is engaged in to developing, manufacturing and marketing injectable pharmaceutical products. The company produces generic injectable pharmaceutical products in more than 300 dosages and formulations. The company focuses mainly in the oncology, anti-infective and critical care markets. The company is located in Schaumburg, IL.
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 10 ans |
| Leonard Shapiro | M | 96 |
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL
American Pharmaceutical Partners, Inc.
American Pharmaceutical Partners, Inc. Pharmaceuticals: MajorHealth Technology American Pharmaceutical Partners, Inc. is engaged in to developing, manufacturing and marketing injectable pharmaceutical products. The company produces generic injectable pharmaceutical products in more than 300 dosages and formulations. The company focuses mainly in the oncology, anti-infective and critical care markets. The company is located in Schaumburg, IL.
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 9 ans |
| Nicole S. Williams | F | 79 |
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL
American Pharmaceutical Partners, Inc.
American Pharmaceutical Partners, Inc. Pharmaceuticals: MajorHealth Technology American Pharmaceutical Partners, Inc. is engaged in to developing, manufacturing and marketing injectable pharmaceutical products. The company produces generic injectable pharmaceutical products in more than 300 dosages and formulations. The company focuses mainly in the oncology, anti-infective and critical care markets. The company is located in Schaumburg, IL. | 4 ans |
| Mitchall G. Clark | M | 63 |
American Bioscience, Inc.
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 5 ans |
| Michael J. Brunelle | M | 65 |
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL
American Bioscience, Inc.
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 5 ans |
| V. Dat Nguyen | M | - |
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL
American Bioscience, Inc.
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 5 ans |
| Nicholas Everett | M | - |
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL
American Bioscience, Inc.
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 5 ans |
| Robert H. Murdock | M | - |
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL
American Bioscience, Inc.
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 5 ans |
| Ronald Allen Louks | M | 59 | - |
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| Etats-Unis | 99 | 100,00% |
| Canada | 0 | -.--% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Patrick Soon-Shiong
- Réseau Personnel